secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telesis Bio Inc. (—)
CIK:        0001850079
Form:       8-K
Filed at:   2024-04-18T23:59:59+00:00
Accession:  0000950170-24-045313
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telesis Bio appoints Eric Esser as CEO; shifts focus to Gibson SOLA EDS and BioXp mRNA
--------------------------------------------------------------------------------

- Eric Esser named President and CEO effective April 16, 2024, replacing founder Todd Nelson who remains on board.
- Esser receives $490k base salary, 100% target bonus, 100k RSUs, and 200k stock options.
- Operating expenses reduced from $14.3M (Q4 2022) to $10.8M (Q4 2023), extending cash runway.
- Commercial focus on Gibson SOLA enzymatic DNA synthesis; secured co-development deal with automation provider.
- BioXp focused on mRNA synthesis; distribution agreement with Avantor expands channel reach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850079/000095017024045313/0000950170-24-045313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850079/000095017024045313/tbio-20240417.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-045313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer